A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetine (ATX) was to assess treatment response rates in children and adolescents with attention-deficit hyperactivity disorder (ADHD) and an inadequate response to methylphenidate (MPH). The primary efficacy and safety outcomes of the study, SPD489-317 (ClinicalTrials.gov NCT01106430), have been published previously
Introduction and objectives: Lack of consensus regarding how best to define treatment response hinde...
In this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylat...
Atomoxetine was first licensed to treat attention-deficit/hyperactivity disorder (ADHD) in children ...
A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetin...
OBJECTIVES: A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) an...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives A seco...
Attention-deficit/hyperactivity disorder (ADHD) is associated with functional impairments in multipl...
OBJECTIVES: The aim of this study was to compare the efficacy and safety of the prodrug psychostimul...
Background: Following the approval of lisdexamfetamine dimesylate (LDX) in several European countrie...
Introduction and objectives: Lack of consensus regarding how best to define treatment response hinde...
In this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylat...
Atomoxetine was first licensed to treat attention-deficit/hyperactivity disorder (ADHD) in children ...
A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) and atomoxetin...
OBJECTIVES: A secondary objective of this head-to-head study of lisdexamfetamine dimesylate (LDX) an...
The Author(s) 2014. This article is published with open access at Springerlink.com Objectives A seco...
Attention-deficit/hyperactivity disorder (ADHD) is associated with functional impairments in multipl...
OBJECTIVES: The aim of this study was to compare the efficacy and safety of the prodrug psychostimul...
Background: Following the approval of lisdexamfetamine dimesylate (LDX) in several European countrie...
Introduction and objectives: Lack of consensus regarding how best to define treatment response hinde...
In this phase 3 extension study, the long-term maintenance of efficacy of lisdexamfetamine dimesylat...
Atomoxetine was first licensed to treat attention-deficit/hyperactivity disorder (ADHD) in children ...